Genprex, Inc.

Company Snapshot: Genprex, Inc.

Last Change Volume High Low

Company Overview

Genprex, Inc. is a clinical stage gene therapy company developing a new approach to treating cancer, based upon a novel proprietary technology platform, including Genprex’s initial product candidate, Oncoprex™ immunogene therapy for non-small cell lung cancer (NSCLC). Genprex’s platform technologies are designed to administer cancer fighting genes by encapsulating them into nanoscale hollow spheres called nanovesicles, which are then administered intravenously and taken up by tumor cells where they express proteins that are missing or found in low quantities. Oncoprex has a multimodal mechanism of action whereby it interrupts cell signaling pathways that cause replication and proliferation of cancer cells, re-establishes pathways for apoptosis, or programmed cell death, in cancer cells, and modulates the immune response against cancer cells. Oncoprex has also been shown to block mechanisms that create drug resistance.

Client News

  1. Dec 3 2018 Genprex to Present at the 11th Annual LD Micro Main Event
  2. Nov 20 2018 Genprex Provides Clinical and Corporate Update for Third Quarter 2018
  3. Oct 30 2018 Genprex Appoints Jan Stevens, RN, as Vice President of Clinical Operations
  4. Oct 1 2018 Genprex to Present at Upcoming Investor and Industry Conferences
  5. Sep 27 2018 Genprex™ Taps Aldevron to Supply TUSC2 Plasmid DNA for Oncoprex Clinical Development Program